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Running title: SMA type II with eosinophilic oesophagitis. 
 
Abstract 
Although primarily characterised by loss of motor neurons from the anterior horn of spinal 
cord and muscle atrophy, spinal muscular atrophy (SMA) is now recognised as a multi-
systemic disorder. Here, we report two SMA Type II patients with eosinophilic oesophagitis 
(EoE), a rare, chronic immune/antigen-mediated condition. One patient presented with 
dysphagia and poor weight gain, and the second patient had symptoms of gastro-oesophageal 
reflux (GOR) and poor weight gain. In both patients, macroscopic observations during 
gastroscopy indicated typical signs of EoE, which were verified during histological 
examination of oesophageal biopsies. Given that there is a specific treatment strategy for 
EoE, these cases highlight the importance of considering this condition in clinical 
investigations - especially for patients with SMA - who have GOR, discomfort, and oral 
aversion.  
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1. Introduction 
The inherited neuromuscular disease, spinal muscular atrophy (SMA), is primarily 
characterised by loss of lower motor neurons from the anterior horn of spinal cord and 
subsequent atrophy of skeletal muscle. The cause of SMA for >95% of patients is a loss-of-
function defect in the SMN1 gene, resulting in reduced levels of the survival of motor neuron 
(SMN) protein [1]. Most humans possess at least one copy of an additional - and almost 
identical - SMN2 gene, but protein translated from SMN2 is much less stable and unable to 
fully compensate for loss of SMN1 [2, 3]. The severity of the disease is largely dependent 
upon the number of SMN2 copies that are present, and as such, patients with the most severe 
phenotypes typically – but not always - have a lower copy number of SMN2 [4]. The disease 
is broadly subdivided into four clinical sub-types, depending on the developmental 
milestones that are reached: type I (severe), type II (intermediate), type III (mild) and type IV 
(adult-onset) [5]. 
 
Although lower motor neurons appear to be particularly vulnerable to low levels of SMN [6], 
numerous reports of symptoms extending far beyond the motor neuron in SMA patients and 
mouse models have resulted in SMA being recognised, in recent years, as a multi-systemic 
disorder [7, 8]. In patients with Type I SMA, for example, there have been reports of 
congenital heart defects, vascular defects, sensory neuronopathy, various pathologies of the 
spleen, abnormalities associated with the autonomic nervous system, and widespread 
metabolic abnormalities, including hyperglycemia, hyperlipidemia, and abnormal fatty acid 
metabolism [reviewed in 7, 8].  
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Here, we report on two SMA Type II patients presenting with a rare condition known as 
eosinophilic oesophagitis (EoE), and discuss the findings in context with what is known 
about the aetiology of EoE. 
 
2. Case reports 
Full parental consent was given for both patients described, before the drafting of this paper. 
 
2.1. Patient 1 
A male child with Type II SMA presented with persistent food aversion, poor weight gain, 
and apparent pain with eating at the age of three years. His weight had remained static on the 
2nd centile at 12kg and was complicated by hypoglycaemic episodes. A gastroscopy (OGD) 
examination revealed signs of reflux oesophagitis but no features of EoE were noted at the 
time. A gastrostomy was subsequently arranged for supplementary feeding, and adlib oral 
intake was encouraged. At five years of age he underwent a second OGD examination with a 
percutaneous endoscopic gastrostomy (PEG) change, and analysis of his oesophageal biopsy 
taken during the examination revealed signs consistent with EoE (Figure 1a). This was 
characterised by the presence of 37 eosinophils per high power field (phpf); in line with the 
North American Society for Pediatric Gastroenterology, Hepatology and Nutrition 
(NASPGHAN) consensus guidelines for diagnosis of EoE (i.e. >20phpf) [9]. Macroscopic 
observation at OGD indicated typical signs of EoE, characterised by a furrowed and 
thickened oesophagus. The patient was subsequently treated with esomeprazole at 10mg daily 
and Budesonide at 500mg, given twice daily as Budesonide nebules mixed with Candorel 
sweetener. He was switched to PediaSure Peptide-based feed (400mls overnight and 200mls 
in day), and cow’s milk protein was excluded from his oral diet (this should continue to be 
the case, assuming patient compliance). His oral intake subsequently improved, and he 
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crossed the centile charts with a weight gain of 6kg in three years since presentation. At six 
years of age, it was noted that the patient no longer had symptoms of EoE and a third OGD 
examination appeared normal. The biopsies taken during this time also appeared normal, 
though only distal biopsies were taken instead of throughout oesophagus, as per 
recommendations [9]). Whilst he had been tested for allergens and was not overtly atopic, it 
was reported, previous to the EoE diagnosis, that he had excessive abdominal rumbling 
noises when given milk or cheese. 
 
2.2. Patient 2 
A female, also with Type II SMA, presented with persistent gastro-oesophageal reflux and 
poor weight gain at the age of 7 years and 6 months. Upon presentation, her weight was only 
14kg, and treatment with 40mg of esomeprazole once daily was started empirically. An 
endoscopy investigation was undertaken when the patient was 10 years of age, whilst 
undergoing a PEG insertion for supplementary nutrition with adlib oral intake (initially, the 
formula was Osmolite, but this was later changed to the higher fibre formula, Ensure 
TwoCal). Though some scattered eosinophils were noted in the oesophagus biopsy, the 
number did not meet the criteria for diagnosis of EoE, and the oesophagus had a normal 
macroscopic appearance. Shortly after, the patient underwent scoliosis surgery, but despite 
this, continued to suffer gastro-oesphageal reflux (GOR) symptoms.  
 
At 14 years of age, another endoscopy investigation during PEG change revealed furrowing 
of the oesophagus with friable mucosa. Up to 20 eosinophils phfp were detected in sections 
taken from her oesophageal biopsy, and though not conclusive, the finding indicated the 
possibility of EoE as differential diagnosis to explain the symptoms of GOR. A follow-up 
endoscopy, 4 months later, revealed thickening of the oesophagus and microscopic changes, 
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including eosinophillic degranulation and a count of 50 eosinophils phpf, both of which were 
consistent with a diagnosis of EoE (Figure 1b). The possibility of switching to a milk-free 
diet was discussed with the patient, but she declined on the basis that her oral intake was so 
limited. Ten weeks following diagnosis, the patient presented with symptoms of dysphagia, 
and subsequently commenced topical steroid treatment in the form of viscous Budesonide at 
1mg, twice daily. Following a ten-week trial, however, the patient and her family reported 
that it had resulted in little perceived benefit, so Budesonide treatment was halted. Three 
months following this, an OGD examination revealed further thickening of the oesophagus, 
though the eosinophil count had reduced slightly, to 20 phpf, since the previous investigation.  
One year later, the patient reported that there had been a slight improvement in symptoms. 
Whilst not overtly atopic, she had been taking antihistamines for hay fever, and when she 
stopped them taking them, reported a return of her GOR symptoms and halitosis. 
  
3. Histological analysis of oesophagi from severe SMA mice 
To determine whether EoE could be concomitant with SMA, histological analyses were 
performed on a series of oesophageal sections from late-symptomatic (postnatal day 8) mice 
with a severe SMA phenotype and age-matched controls. Taiwanese (Smn-/-; SMN2tg/0) 
SMA mice [10, 11], on a congenic FVB background, were generated from stocks originally 
obtained from Jackson Laboratories, maintained according to established breeding protocols 
[11, 12]. Phenotypically normal heterozygous (Smn+/-; SMN2tg/0) littermates were used for 
controls. Mice were genotyped using standard PCR methods. Animal breeding was 
performed in accordance with institutional guidelines and under appropriate UK Home Office 
personal and project licenses. All mice were maintained under standard specific pathogen-
free conditions in animal care facilities at the University of Edinburgh. 
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Oesophagi from late-symptomatic (P8) SMA (n=3) and control mice (n=3) were removed 
immediately following sacrifice by cutting transversely through the base of skull and at the 
level of the L1 vertebrae. The neck, spinal column, dorsal ribcage and diaphragm were kept 
attached to the oesophagus to provide structural support. Specimens were fixed in 4% 
paraformaldehyde, transferred to 30% sucrose and then embedded in optimal cutting 
temperature compound (OCT). The oesophaus, with supporting structures, was sectioned at 
10μm on a cryostat and sections from the cervical, proximal thoracic and distal thoracic 
regions were collected onto slides. Five sections from each of these areas (from each mouse) 
were stained with haematoxylin and eosin using a standard protocol. Images were captured 
using a Nikon Eclipse 80i microscope, fitted with Nikon camera, and operated with the NiS 
Elements computer software. 
 
The captured images were analysed by two independent assessors; neither of whom 
positively identified the presence of eosinophils in any of the oesophageal sections examined 
from SMA or age-matched control mice. In addition, there were no apparent morphological 
differences seen between the oesophagi of SMA and control mice (Figure 2).  
 
4. Discussion 
To the best of our knowledge, these are the first formally reported cases of EoE coexisting 
with SMA. EoE is considered to represent a chronic immune/antigen-mediated oesophageal 
disease, characterised by symptoms of oesophageal dysfunction in subjects who typically 
have indicators of an atopic tendency [13]. With an incidence of EoE currently estimated at 
0.16-4 per 10,000 [13-15], coupled with an incidence of Type II SMA within a similar range 
[16], it is very surprising to observe the two conditions presenting concurrently within a small 
geographically-defined patient cohort.  
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Symptoms of gastrointestinal (GI) dysfunction in SMA patients, including oesophageal 
reflux, are widely reported and are a major contributor to mortality and morbidity [17]. It is 
generally accepted that there is an anatomical association between scoliosis and GI problems 
[18], evidenced by the fact that patients with inherited connective tissue disorders (CTDs) for 
whom scoliosis is a common condition, for example, also have a high rate of 
gastroesophageal reflux disease [19]. It has been suggested that CTD patients are at an 8-fold 
risk of EoE compared with the general population [19], raising the possibility that EoE may 
simply represent a symptom in a spectrum of “normal reflux”. Intriguingly, however, the 
same study also reported that 15 out of 42 patients with EoE-CTD responded to dietary-based 
interventions, thus indicating that their EoE was allergen-mediated rather than a consequence 
of primary reflux [19]. This therefore raises the possibility that EoE may, at least in some 
circumstances, be a consequence of immune / molecular dysfunction.  
 
There is no evidence at this stage to suggest a concomitant association of EoE with SMA, but 
the finding that some GI symptoms in SMA patients have been attributed to molecular 
dysfunction [20], coupled with reports of immune dysregulation in SMA patients and mouse 
models [21, 22], clearly justifies the need for further research.  When doing so, however, it 
will be important to consider that laboratory mice are unlikely to have been exposed to the 
type of environmental or food-based antigens that may be necessary to trigger 
immune/antigen-mediated oesophageal disease [23]. (In this study, for example, the mice 
were still feeding on milk from their mother who was fed a standard milk-free pellet feed, 
RM3, from Special Diets Services).  
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In conclusion, the cases described above highlight the importance of considering EoE in 
clinical investigations of patients who have GOR, discomfort, and oral aversion, even when 
neurological reasons may appear to explain symptoms.  
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Figures and figure legends 
Figure 1: Intraepithelial eosinophils in the oesophageal squamous epithelium of two 
SMA patients. Representative haematoxylin and eosin stained images of oesophageal biopsy 
sections from patient 1 (A) and patient 2 (B), both showing signs consistent with EoE. This 
was characterised by the presence of 37 eosinophils per high power field (in line with the 
NASPGHAN guidelines for diagnosis of EoE (i.e. >20phpf) [3]). Arrows point to some of the 
eosinophils that were present. Images were captured on a Nikon eclipse 80i microscope. 
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Figure 2: Eosinophils were not detected in oesophageal sections from severe SMA mice. 
Representative haematoxylin and eosin stained images of each region of the oesophagus (i.e. 
cervical, proximal thoracic and thoracic) are shown. (Five sections per region were analysed 
from three SMA mice and three age-matched control mice). Scale bar = 10µm. 
 
